
Gilead Sciences statistics
$168.08+0.08%Close 13 Nov 2026 · Market value $210.1B
Valuation and share-price figures are struck on the latest close (13 Nov 2026); the others are read from the company's reports. A figure that cannot be worked out, such as a P/E after a loss, is left out.
Valuation
Gilead Sciences is valued at $210.1B on its latest close.
| Market value | $210.1B |
|---|
| Enterprise value | $228.4B |
|---|
| Price / sales | 6.78 |
|---|
| Price / book | 16.11 |
|---|
| EV / EBITDA | 505.27 |
|---|
| EV / sales | 7.37 |
|---|
| Price / free cash flow | 15.25 |
|---|
| Price / free cash flow, own 5-year average | 12.56 |
|---|
| EV / free cash flow | 16.69 |
|---|
| Free cash flow yield | 6.6% |
|---|
| Dividend yield | 2.0% |
|---|
Share price
| Latest close | $168.08 |
|---|
| Day's change | +0.1% |
|---|
| 52-week high | $176.58 |
|---|
| 52-week low | $116.88 |
|---|
| From 52-week high | −4.8% |
|---|
| Return · 1 month | +7.6% |
|---|
| Return · 3 months | +17.2% |
|---|
| Return · year to date | +36.9% |
|---|
| Return · 1 year | +36.2% |
|---|
| Beta · 1 year against the S&P 500 | 0.37 |
|---|
| 50-day average | $155.10 |
|---|
| 200-day average | $141.72 |
|---|
| RSI 14 | 59.3 |
|---|
| Average volume · 20 sessions | 6.6M |
|---|
Margins and returns
For fiscal 2025, as filed.
| Gross margin | 78.8% |
|---|
| Operating margin | 34.0% |
|---|
| Net margin | 28.9% |
|---|
| Free cash flow margin | 32.1% |
|---|
| Return on equity | 40.5% |
|---|
| Return on assets | 14.8% |
|---|
| Return on invested capital | 20.4% |
|---|
| Return on invested capital, 5-year average | 12.0% |
|---|
| Return on capital employed | 21.3% |
|---|
| Stock-based compensation / revenue | 3.0% |
|---|
Financial position
At the end of fiscal 2025.
| Cash and equivalents | $7.56B |
|---|
| Total debt | $25.54B |
|---|
| Net debt | $17.91B |
|---|
| Current ratio | 1.55 |
|---|
| Quick ratio | 0.95 |
|---|
| Debt / equity | 1.13 |
|---|
| Net debt / EBITDA | 1.40 |
|---|
| Interest coverage | 9.79 |
|---|
Growth
| Revenue, latest quarter on a year | +6.8% |
|---|
| Revenue, twelve months on a year | +6.5% |
|---|
| EPS, latest quarter on a year | −20.2% |
|---|
| EPS, twelve months on a year | −148% |
|---|
| Revenue, 5-year compound | +3.6% |
|---|
| Revenue, 10-year compound | −1.0% |
|---|
| Net income, 5-year compound | +133% |
|---|
| Free cash flow, 5-year compound | +4.7% |
|---|
| EPS, 5-year compound | +134% |
|---|
Shares and dividends
For fiscal 2025, as filed.
| Diluted shares | 1.3B |
|---|
| Shares outstanding, 5-year compound | −0.1% |
|---|
| Net share repurchases | $1.51B |
|---|
| Dividends per share | $3.16 |
|---|
| Dividend payout | 47.0% |
|---|
Taxes
For fiscal 2025, as filed.
| Income tax expense | $1.29B |
|---|
| Effective tax rate | 13.1% |
|---|
GILD in the terminal
Valuation against the company's own history, a cash-flow valuation, peers, charts and alerts.